The study by Parida et al. (2022) implies that brain metastases in patients with HER2-enriched breast cancer may exhibit resistance to HER2 inhibitors by bolstering reactive oxygen species neutralization through xCT activation. The gene discussed is ERBB2; the disease is breast cancer.